Inside Precision Medicine January 12, 2026
Jonathan D. Grinstein, PhD

Eric Kelsic, CEO and co-founder, unveils Dyno-yp2, adding strategic delivery agility to overcome safety concerns plaguing CNS targeting

Eric Kelsic, PhD, has spent years thinking about how to target the brain for therapy. Through his career, Kelsic has seen central nervous system (CNS) programs rely heavily on brute force: local CNS injections offer limited benefit, are invasive and unscalable, and systemic adeno-associated virus (AAV) delivery largely fails due to blood-brain barrier (BBB) exclusion, liver sequestration, and, ultimately, toxicity. To Kelsic and others, the bottleneck is clear—get through the BBB and keep clear of the liver.

Many companies have seeded with the mission to engineer AAVs to get through the BBB, including Dyno Therapeutics—Dyno Tx for short—co-founded in 2018 by Kelsic...

Today's Sponsors

Venturous
ZeOmega

Today's Sponsor

Venturous

Continue Reading

 
Topics: AI (Artificial Intelligence), Biotechnology, Conferences / Podcast, Pharma / Biotech, Technology, Trends
Related Articles:
283: A candid conversation: Physicians on the front lines of GLP‑1 care
BigHat, Revvity Collaborate with Eli Lilly, Immunai Signs Agreement with Bristol Myers Squibb, SandboxAQ Launches New AI Model
NVIDIA and Lilly Announce Co-Innovation AI Lab to Accelerate Drug Discovery
Data Visualization is Broken in Biotech: Q&A with Sunitha Venkat
Biotech investor Cormorant secures $150M for another SPAC deal

Share Article